

|  |  |   |
|--|--|---|
| <b>Statement of Deficiencies</b>   | <b>(X1) Provider/Supplier/CLIA Identification Number</b><br><br>13D0521010 | <b>(X3) Date Survey Completed</b><br><br>03/10/2022 |
| <b>Name of Provider or Supplier</b><br><br>Rexburg Medical Center  | <b>Street Address, City, State</b><br><br>393 E 2nd North, Rexburg, ID     |   |
| For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency. |  |   |

| <b>(X4) ID Prefix Tag</b> | <b>Summary Statement of Deficiencies</b>  |
|---------------------------|---|
| <b>D2016</b>              | <p><b>SUCCESSFUL PARTICIPATION</b><br/>CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by:<br/>Based on a Proficiency Testing (PT) desk review of the Centers for Medicare and Medicaid (CMS) PT data report (Report 155D) and graded results from the American Proficiency Institute (API), the laboratory failed to successfully participate and achieve an overall satisfactory score for two (2) of three (3) testing events in 2021 for the specialty of hematology. See D2123, D2130</p> |
| <b>D2123</b>              | <p><b>HEMATOLOGY</b><br/>CFR(s): 493.851(c)</p>   |

Failure to participate in a testing event is unsatisfactory performance and results in a score of 0 for the testing event. Consideration may be given to those laboratories failing to participate in a testing event only if-- (1) Patient testing was suspended during the time frame allotted for testing and reporting proficiency testing results; (2) The laboratory notifies the inspecting agency and the proficiency testing program within the time frame for submitting proficiency testing results of the suspension of patient testing and the circumstances associated with failure to perform tests on proficiency testing samples; and (3) The laboratory participated in the previous two proficiency testing events.

This STANDARD is not met as evidenced by:  
Based on a Proficiency Testing (PT) desk review of the Centers for Medicare and Medicaid (CMS) PT data report (Report 155D), graded PT results from the American Proficiency Institute (API) and a telephone interview with the technical consultant on 3/10/2022, the laboratory failed to participate in one (1) of three (3) testing events in 2021 for the specialty of hematology. The findings include: 1. A PT desk review of Report 155D and graded PT results from API identified that the laboratory failed to participate in testing for event three (3) in 2021 for the specialty of hematology for the analytes: white blood cell (WBC) differential, erythrocyte (RBC) count, hematocrit (HCT), hemoglobin (HGB), leukocyte (WBC) count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), platelet (PLT) count, and red cell distribution width (RDW) resulting in scores of zero (0). 2. A telephone interview with the technical consultant on 3/10/2022 at 10:30 am confirmed the above findings.

**D2130**

**HEMATOLOGY**  
CFR(s): 493.851(f)

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:  
Based on a Proficiency Testing (PT) desk review of the Centers for Medicare and Medicaid (CMS) PT data report (Report 155D), graded PT results from the American Proficiency Institute (API) and telephone interview with the technical consultant on 3/10/2022, the laboratory failed to successfully participate and achieve an overall satisfactory score for two (2) of three (3) testing events in 2021 for the specialty of hematology for the analyte white blood cell (WBC) differential. The findings include: 1. A PT desk review of Report 155D and graded PT results from API identified that the laboratory failed to achieve overall satisfactory scores for events two (2) and three (3) in 2021 for the specialty of hematology for the analyte WBC differential. Analyte Year Event Score WBC Differential 2021 2 28% WBC Differential 2021 3 0% 2. A telephone interview with the technical consultant on 3/10/2022 at 10:30 am confirmed the above findings.